Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2010. Start Trial.
Date Value
September 30, 2026 51.95M
June 30, 2026 51.91M
March 31, 2026 50.05M
December 31, 2025 49.33M
September 30, 2025 45.59M
June 30, 2025 20.52M
March 31, 2025 17.10M
December 31, 2024 17.03M
September 30, 2024 17.03M
June 30, 2024 16.99M
March 31, 2024 16.99M
December 31, 2023 16.95M
September 30, 2023 16.95M
June 30, 2023 10.99M
March 31, 2023 10.92M
December 31, 2022 8.244M
September 30, 2022 7.406M
June 30, 2022 7.367M
March 31, 2022 7.355M
December 31, 2021 6.841M
September 30, 2021 5.966M
June 30, 2021 5.959M
March 31, 2021 5.955M
December 31, 2020 4.941M
September 30, 2020 4.524M
Date Value
June 30, 2020 4.044M
March 31, 2020 4.021M
December 31, 2019 3.979M
September 30, 2019 3.979M
June 30, 2019 3.946M
March 31, 2019 3.943M
December 31, 2018 3.938M
September 30, 2018 3.090M
June 30, 2018 2.666M
March 31, 2018 2.550M
December 31, 2017 2.545M
September 30, 2017 2.482M
June 30, 2017 2.269M
March 31, 2017 2.269M
December 31, 2016 2.267M
September 30, 2016 2.267M
June 30, 2016 2.266M
March 31, 2016 2.266M
December 31, 2015 2.264M
September 30, 2015 2.222M
June 30, 2015 2.219M
March 31, 2015 2.217M
December 31, 2014 2.186M
September 30, 2014 2.185M
June 30, 2014 2.169M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Relmada Therapeutics, Inc. 106.69M
Journey Medical Corp. 28.23M
ANI Pharmaceuticals, Inc. 22.90M
Corcept Therapeutics, Inc. 109.36M
Veru, Inc. 17.05M